- Home
- TSHA vs GAU Comparison
TSHA vs GAU Comparison
Compare TSHA & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- GAU
- Stock Information
- Founded
- TSHA 2019
- GAU 1999
- Country
- TSHA United States
- GAU Canada
- Employees
- TSHA N/A
- GAU N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- GAU
- Sector
- TSHA Health Care
- GAU
- Exchange
- TSHA Nasdaq
- GAU Nasdaq
- Market Cap
- TSHA 356.7M
- GAU 323.9M
- IPO Year
- TSHA 2020
- GAU N/A
- Fundamental
- Price
- TSHA $1.29
- GAU $1.17
- Analyst Decision
- TSHA Strong Buy
- GAU Strong Buy
- Analyst Count
- TSHA 8
- GAU 1
- Target Price
- TSHA $6.63
- GAU $2.80
- AVG Volume (30 Days)
- TSHA 2.4M
- GAU 867.8K
- Earning Date
- TSHA 05-13-2025
- GAU 05-01-2025
- Dividend Yield
- TSHA N/A
- GAU N/A
- EPS Growth
- TSHA N/A
- GAU N/A
- EPS
- TSHA N/A
- GAU 0.02
- Revenue
- TSHA $8,333,000.00
- GAU $231,339,000.00
- Revenue This Year
- TSHA N/A
- GAU $58.96
- Revenue Next Year
- TSHA N/A
- GAU $39.24
- P/E Ratio
- TSHA N/A
- GAU $58.50
- Revenue Growth
- TSHA N/A
- GAU N/A
- 52 Week Low
- TSHA $1.17
- GAU $1.07
- 52 Week High
- TSHA $4.32
- GAU $2.00
- Technical
- Relative Strength Index (RSI)
- TSHA 33.64
- GAU 39.48
- Support Level
- TSHA $1.17
- GAU $1.22
- Resistance Level
- TSHA $1.87
- GAU $1.30
- Average True Range (ATR)
- TSHA 0.17
- GAU 0.06
- MACD
- TSHA -0.06
- GAU -0.02
- Stochastic Oscillator
- TSHA 12.18
- GAU 4.84
Stock Price Comparison Chart: TSHA vs GAU
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages the Asanko Gold Mine, located in Ghana, West Africa. Its Asanko Gold Mine is a multi-deposit complex, with two main deposits, the Obotan Project and the Esaase Project, both located in the Amansie West District of the Republic of Ghana, West Africa.